IgY(ΔFc) Antibody-Derived Biotherapeutics, Nutraceuticals, and Diagnostics: Unlocking Strategic Partnership Opportunities
Duck IgY(ΔFc) Antibody Proprietary Technology Platform
Good Biotech Corp. is a fully integrated biotechnology company specializing in the development, manufacturing, and commercialization of Duck IgY(ΔFc) antibodies derived from duck egg yolks for diagnostic and therapeutic applications. As the world’s only manufacturer of this state-of-the-art technology, we have successfully built a groundbreaking Duck IgY(ΔFc) antibody platform, validated through multiple FDA 510(k)-cleared products.
Our innovative technology has been applied across diverse fields, including:
- Next-generation immunoturbidimetric assay kits (FDA 510(k) cleared)
- Life science research products
- Point-of-care diagnostic products
- Biotherapeutics
Leveraging the unique advantages of Duck IgY(ΔFc) antibodies, Good Biotech is advancing novel biotherapeutics, including:
- The integrated IgY(ΔFc) Snakebite Solution: Rapid POCT Kit for Snakebite Diagnosis & Superior IgY(ΔFc)-derived Snake Antivenom Immunoglobulins for Precision Therapy
- Digoxin Immune Fab (for digoxin toxicity & severe preeclampsia)
- Duck IgY(ΔFc) Immunoglobulins: a target treatment for nosocomial MDR Staphylococcus aureus infections
- Anti-obesity nutraceuticals & functional foods
- Gastrointestinal health products & anti-caries treatments
We remain committed to expanding applications of Duck IgY(ΔFc) antibodies to address critical medical challenges.
Addressing Unmet Global Medical Needs
Current antivenoms, antitoxins, and antidotes rely heavily on equine and ovine-based polyclonal antibodies, which suffer from low efficacy, high costs, and serious allergic risks. Additionally, these biologicals often face global shortages, creating urgent demand for safer, more effective alternatives.
Our Duck IgY(ΔFc) antibody platform offers superior advantages, including:
✔ Higher neutralizing activity for enhanced efficacy
✔ Scalable & cost-effective production
✔ Simpler downstream processing for rapid development
✔ No allergenicity or biohazard risks (TSE-free)
✔ Ethical, animal-friendly production
In alignment with the World Health Organization (WHO) initiative to ensure safe, effective, and affordable therapeutic antibodies, Good Biotech’s next-generation biotherapeutics are poised to play a pivotal role in the future of specialty pharmaceuticals.
Strategic Partnerships
Good Biotech Corp. (GBC) has successfully commercialized and validated its Duck IgY(ΔFc) antibody technology with FDA 510(k)-cleared clinical diagnostic products and expanding biotherapeutic applications. Our cutting-edge platform offers transformative solutions for serious diseases and unmet medical needs.
Partnership Opportunities (Click on each item for more details) :
🔹 IgY(ΔFc) Immunoglobulins: A Target Treatment for Nosocomial MDR Staphylococcus aureus Infections
🔹 The Intergrated Snakebite Solution: Rapid POCT Kit & Superior IgY(ΔFc)-derived Snake Antivenom Immunoglobulins for Precision Therapy
🔹 IgY(ΔFc)-derived Digoxin Immune Fab
🔹 IgY(ΔFc) Nutraceuticals for Obesity Control
🔹 IgY(ΔFc)-based Anti-Rabies & Anti-Botulism Immunoglobulins
🔹 IgY(ΔFc) Antibody for Severe Malaria Treatment, including MDR Malaria
🔹 Neutralizing IgY(ΔFc) Antibodies for Functional Foods, Oral Health Products, and Skin Healthcare Solutions
Join Us as a Strategic Partner
Good Biotech’s innovative antibody technology presents a unique opportunity for global pharmaceutical companies seeking innovative solutions in biotherapeutics and diagnostics. We are seeking strategic partners who can leverage our Duck IgY(ΔFc) technology platform to develop innovative products for critical healthcare needs.
If you are interested in exploring a partnership, contact our Business Development Team at:
📧 partnering@good-biotech.com
Together, we can drive innovation and advance global healthcare with Duck IgY(ΔFc) technology.
